Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Estrogen signaling pathway (mmu04915)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Adcy1
KLA  ATP  ATP+KLA
 BC050125 adenylate cyclase 1, mRNA (cDNA clone IMAGE:30015692). [BC050125] KLA 1.05 1.03 .98 1.04 1.05 1.09 1.10
ATP .90 1.02 .99 .97 1.03 .95 1.01
KLA/ATP .99 1.04 .90 .98 .98 1.00 1.03
Adcy1
KLA  ATP  ATP+KLA
 NM_009622 adenylate cyclase 1 (Adcy1), mRNA [NM_009622] KLA 1.07 1.02 1.06 1.07 1.03 1.02 1.01
ATP 1.02 1.04 1.00 .99 .99 .95 .97
KLA/ATP .97 1.05 1.02 1.05 1.01 .98 1.05
Adcy2
KLA  ATP  ATP+KLA
 NM_153534 adenylate cyclase 2 (Adcy2), mRNA [NM_153534] KLA .79 .82 .83 .73 .61 .66 .90
ATP 1.10 1.09 1.02 1.04 .88 .58 .53
KLA/ATP .84 .87 .77 .75 .68 .60 .43
Adcy3
KLA  ATP  ATP+KLA
 NM_138305 adenylate cyclase 3 (Adcy3), mRNA [NM_138305] KLA .84 .84 .83 .78 .66 .55 .49
ATP 1.09 1.05 .89 1.02 .84 .62 1.52
KLA/ATP .93 .87 .75 .85 .66 .83 .77
Adcy4
KLA  ATP  ATP+KLA
 NM_080435 adenylate cyclase 4 (Adcy4), mRNA [NM_080435] KLA 1.05 1.07 .96 1.00 1.04 1.05 1.05
ATP 1.02 1.05 1.02 1.48 1.37 1.08 1.09
KLA/ATP 1.00 1.05 .91 1.19 1.35 1.27 1.08
Adcy5
KLA  ATP  ATP+KLA
 NM_001012765 adenylate cyclase 5 (Adcy5), mRNA [NM_001012765] KLA 1.06 1.00 .97 1.01 1.03 .95 .93
ATP .95 1.08 1.08 1.07 .97 1.03 .97
KLA/ATP .97 .92 1.04 .99 .91 .96 1.04
Adcy6
KLA  ATP  ATP+KLA
 NM_007405 adenylate cyclase 6 (Adcy6), mRNA [NM_007405] KLA 1.10 1.16 1.16 1.09 1.08 1.06 .99
ATP 1.05 .97 1.08 1.12 1.08 1.08 1.04
KLA/ATP 1.14 1.20 1.29 1.30 1.25 1.11 1.07
Adcy7
KLA  ATP  ATP+KLA
 NM_001037724 adenylate cyclase 7 (Adcy7), transcript variant 3, mRNA [NM_001037724] KLA .43 .39 .35 .32 .45 .72 .84
ATP .90 .84 .62 .41 .53 .42 .94
KLA/ATP .39 .34 .23 .17 .41 .34 .67
Adcy7
KLA  ATP  ATP+KLA
 NM_007406 adenylate cyclase 7 (Adcy7), transcript variant 1, mRNA [NM_007406] KLA .51 .52 .48 .41 .59 .81 .99
ATP 1.01 1.02 .62 .52 .53 .38 .98
KLA/ATP .53 .48 .30 .27 .42 .36 .65
Adcy8
KLA  ATP  ATP+KLA
 NM_009623 adenylate cyclase 8 (Adcy8), mRNA [NM_009623] KLA 1.00 1.00 1.07 .97 1.04 .98 1.02
ATP 1.04 1.05 1.14 1.03 .99 1.00 .97
KLA/ATP 1.05 1.04 1.00 1.03 .98 .94 .96
Adcy9
KLA  ATP  ATP+KLA
 NM_009624 adenylate cyclase 9 (Adcy9), mRNA [NM_009624] KLA .18 .15 .13 .15 .17 .19 .33
ATP 1.33 1.16 .97 .98 .62 .56 .86
KLA/ATP .19 .16 .17 .18 .20 .25 .38
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Atf2
KLA  ATP  ATP+KLA
 AK047405 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930056P03 product:activating transcription factor 2, full insert sequence. [AK047405] KLA 1.01 1.00 1.02 1.04 1.03 1.03 1.00
ATP .99 1.00 .95 1.01 1.04 .98 1.03
KLA/ATP 1.07 1.00 .98 .99 1.00 1.03 .93
Atf2
KLA  ATP  ATP+KLA
 NM_001025093 activating transcription factor 2 (Atf2), transcript variant 1, mRNA [NM_001025093] KLA 1.35 1.30 1.32 1.31 1.37 1.09 1.20
ATP 1.15 1.17 .99 1.11 1.22 1.39 1.28
KLA/ATP 1.38 1.42 1.21 1.28 1.17 1.33 1.69
Atf4
KLA  ATP  ATP+KLA
 NM_009716 activating transcription factor 4 (Atf4), mRNA [NM_009716] KLA .91 1.06 1.13 1.31 1.92 2.59 3.01
ATP 1.05 1.14 1.34 2.88 4.84 2.36 2.56
KLA/ATP 1.14 1.08 1.17 2.40 3.72 3.54 3.62
BB548379
KLA  ATP  ATP+KLA
 BB548379 gb|BB548379 RIKEN full-length enriched, 2 days pregnant adult female oviduct Mus musculus cDNA clone E230007L20 3. [BB548379] KLA .98 1.05 1.00 .99 1.04 1.04 1.05
ATP 1.01 .98 1.01 1.02 .98 1.08 .92
KLA/ATP .98 1.06 1.03 1.03 1.00 1.00 .99
Calm1
KLA  ATP  ATP+KLA
 NM_009790 calmodulin 1 (Calm1), mRNA [NM_009790] KLA 1.20 1.26 1.30 1.06 1.16 1.09 1.18
ATP 1.07 1.20 1.00 1.29 .99 .64 .58
KLA/ATP 1.31 1.31 .93 1.31 .97 .83 .59
Calm2
KLA  ATP  ATP+KLA
 NM_007589 calmodulin 2 (Calm2), mRNA [NM_007589] KLA .79 .81 .71 .67 .54 .45 .64
ATP .99 1.03 1.04 .93 .82 .52 .76
KLA/ATP .76 .78 .76 .77 .73 .47 .42
Calm3
KLA  ATP  ATP+KLA
 NM_007590 calmodulin 3 (Calm3), mRNA [NM_007590] KLA .95 .96 .93 1.03 1.05 1.08 1.00
ATP .93 .96 .99 .97 .93 .84 .72
KLA/ATP .89 .93 .90 .91 1.02 .98 .70
Calm4
KLA  ATP  ATP+KLA
 NM_020036 calmodulin 4 (Calm4), mRNA [NM_020036] KLA 1.02 .96 1.05 1.00 .99 1.00 1.01
ATP 1.10 1.05 1.03 1.01 .94 .98 .98
KLA/ATP .99 1.12 1.01 1.03 .98 1.07 1.02
Calm5
KLA  ATP  ATP+KLA
 NM_001008706 calmodulin 5 (Calm5), mRNA [NM_001008706] KLA 1.02 1.11 .99 .98 1.07 1.01 1.09
ATP 1.07 1.05 1.04 1.04 1.01 1.04 .99
KLA/ATP 1.00 1.00 .97 1.07 1.00 1.07 .98
Calml3
KLA  ATP  ATP+KLA
 NM_027416 calmodulin-like 3 (Calml3), mRNA [NM_027416] KLA 1.01 .95 1.05 .91 1.01 .98 .89
ATP .91 1.05 1.04 1.01 .93 1.07 .99
KLA/ATP 1.01 .96 .97 .96 .97 .92 .99
Creb1
KLA  ATP  ATP+KLA
 NM_009952 cAMP responsive element binding protein 1 (Creb1), transcript variant B, mRNA [NM_009952] KLA 1.42 1.33 1.16 .99 .83 .97 .92
ATP .92 .91 1.18 1.38 1.51 1.02 .75
KLA/ATP 1.34 1.31 1.49 1.37 1.71 1.05 .93
Creb3
KLA  ATP  ATP+KLA
 NM_013497 cAMP responsive element binding protein 3 (Creb3), mRNA [NM_013497] KLA 1.21 1.21 1.23 1.53 1.77 1.77 1.31
ATP 1.02 1.03 .99 1.05 .82 .83 1.48
KLA/ATP 1.15 1.18 1.20 1.26 1.13 1.15 1.86
Creb3l1
KLA  ATP  ATP+KLA
 NM_011957 cAMP responsive element binding protein 3-like 1 (Creb3l1), mRNA [NM_011957] KLA 1.18 1.17 1.53 1.28 1.22 1.11 1.23
ATP 1.01 1.09 .98 1.17 1.22 1.01 1.15
KLA/ATP 1.22 1.29 1.08 1.34 1.14 1.36 1.12
Creb3l2
KLA  ATP  ATP+KLA
 AK082964 12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530025K05 product:unclassifiable, full insert sequence [AK082964] KLA .44 .38 .37 .40 .45 .42 .47
ATP .90 .78 1.22 .79 .54 .46 .44
KLA/ATP .41 .41 .49 .43 .50 .51 .23
Creb3l2
KLA  ATP  ATP+KLA
 NM_178661 cAMP responsive element binding protein 3-like 2 (Creb3l2), mRNA [NM_178661] KLA .98 .87 .76 .98 1.03 .87 1.12
ATP 1.20 1.18 1.50 1.35 .86 1.32 1.50
KLA/ATP .98 1.04 1.15 1.05 .79 1.27 1.25
Creb3l3
KLA  ATP  ATP+KLA
 NM_145365 cAMP responsive element binding protein 3-like 3 (Creb3l3), mRNA [NM_145365] KLA .66 .75 .65 .85 1.04 1.44 1.73
ATP 1.02 .98 .97 1.09 .85 .69 1.11
KLA/ATP .70 .66 .71 .83 .80 .85 1.05
Creb3l4
KLA  ATP  ATP+KLA
 NM_030080 cAMP responsive element binding protein 3-like 4 (Creb3l4), mRNA [NM_030080] KLA 1.55 1.42 1.51 1.73 1.76 2.54 1.38
ATP 1.07 .81 .89 1.08 .94 1.08 1.08
KLA/ATP 1.44 1.38 1.44 1.25 1.30 1.26 2.24
Creb5
KLA  ATP  ATP+KLA
 AK051306 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130032G03 product:unclassifiable, full insert sequence. [AK051306] KLA 2.18 2.13 2.42 1.97 1.57 1.94 1.98
ATP 1.11 1.09 1.47 1.74 1.36 1.44 1.62
KLA/ATP 2.55 2.77 3.02 3.15 2.51 2.52 2.61
Creb5
KLA  ATP  ATP+KLA
 NM_172728 cAMP responsive element binding protein 5 (Creb5), mRNA [NM_172728] KLA 3.70 3.60 2.84 2.39 1.92 2.81 1.84
ATP .92 .89 1.19 1.93 1.51 1.55 1.44
KLA/ATP 3.16 3.51 4.33 5.35 5.78 3.23 3.03
Crebl1
KLA  ATP  ATP+KLA
 NM_017406 cAMP responsive element binding protein-like 1 (Crebl1), mRNA [NM_017406] KLA 1.22 1.30 1.32 1.34 1.51 1.52 1.75
ATP 1.13 1.32 1.16 1.66 1.06 .93 1.54
KLA/ATP 1.37 1.25 1.21 1.74 1.04 1.01 2.07
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Esr1
KLA  ATP  ATP+KLA
 NM_007956 estrogen receptor 1 (alpha) (Esr1), mRNA [NM_007956] KLA 1.06 1.05 1.11 1.36 1.33 1.02 .90
ATP 1.05 .92 1.02 .94 1.02 .83 .67
KLA/ATP 1.02 .98 1.09 1.08 1.32 1.07 .71
Esr2
KLA  ATP  ATP+KLA
 NM_207707 estrogen receptor 2 (beta) (Esr2), transcript variant 1, mRNA [NM_207707] KLA 1.00 1.00 1.01 1.00 1.00 1.01 1.02
ATP .99 1.00 1.00 1.00 1.00 1.01 1.01
KLA/ATP 1.00 1.02 .98 .97 1.01 .99 1.00
Fkbp4
KLA  ATP  ATP+KLA
 NM_010219 FK506 binding protein 4 (Fkbp4), mRNA [NM_010219] KLA .82 .87 .90 .71 .67 .55 .77
ATP .99 1.09 1.06 1.30 1.04 .58 .55
KLA/ATP .89 .89 .83 .93 .77 .59 .33
Fkbp5
KLA  ATP  ATP+KLA
 NM_010220 FK506 binding protein 5 (Fkbp5), mRNA [NM_010220] KLA .96 1.02 .97 .89 .71 .69 .60
ATP 1.02 1.06 1.02 1.00 .96 1.04 .70
KLA/ATP 1.03 .99 .90 .98 .84 .86 .67
Fos
KLA  ATP  ATP+KLA
 NM_010234 FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] KLA .42 .33 .64 .61 .71 .85 .71
ATP 3.48 5.46 23.78 25.22 1.71 2.36 1.50
KLA/ATP .90 1.74 5.97 8.62 1.28 2.42 4.52
Gabbr1
KLA  ATP  ATP+KLA
 NM_019439 gamma-aminobutyric acid (GABA-B) receptor, 1 (Gabbr1), mRNA [NM_019439] KLA 1.00 1.03 1.04 1.01 .97 1.01 .99
ATP .98 .96 1.03 1.01 .96 1.03 .99
KLA/ATP .97 1.00 .97 1.02 1.02 .97 1.01
Gabbr2
KLA  ATP  ATP+KLA
 NM_001081141 gamma-aminobutyric acid (GABA) B receptor 2 (Gabbr2), mRNA [NM_001081141] KLA 1.06 .98 .99 1.03 1.09 1.06 1.02
ATP 1.03 1.06 1.05 1.14 1.10 1.00 1.04
KLA/ATP 1.09 1.10 1.12 1.11 1.06 1.04 1.06
Gnai1
KLA  ATP  ATP+KLA
 NM_010305 guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] KLA .95 1.01 1.01 1.00 1.09 1.10 1.08
ATP 1.06 1.06 .99 1.15 1.02 .94 .99
KLA/ATP 1.02 1.04 .99 1.16 1.01 1.02 1.13
Gnai2
KLA  ATP  ATP+KLA
 NM_008138 guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] KLA .74 .79 .82 .74 .91 .97 1.10
ATP 1.07 1.16 .78 1.12 .78 .48 .82
KLA/ATP .91 .81 .53 .80 .60 .68 .87
Gnai3
KLA  ATP  ATP+KLA
 NM_010306 guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] KLA 1.23 1.24 1.14 1.06 .99 1.15 1.09
ATP .96 .93 .86 .64 1.34 2.02 1.35
KLA/ATP 1.20 1.24 .97 .76 1.21 1.62 1.17
Gnao1
KLA  ATP  ATP+KLA
 NM_001113384 guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384] KLA .95 .98 1.03 1.00 1.02 1.02 .99
ATP .95 1.02 1.01 1.08 .99 .97 .95
KLA/ATP 1.05 1.04 1.10 .99 1.01 .98 1.03
Gnao1
KLA  ATP  ATP+KLA
 NM_010308 guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308] KLA .98 .96 1.00 .97 .96 .97 1.01
ATP 1.12 .99 1.05 .87 .97 1.02 1.01
KLA/ATP .93 1.00 .99 1.01 1.05 1.07 .98
Gnaq
KLA  ATP  ATP+KLA
 NM_008139 guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139] KLA .82 .82 .69 .64 .60 .55 .55
ATP 1.06 1.02 .87 .67 .50 .66 .57
KLA/ATP .82 .79 .66 .55 .41 .33 .48
Gnas
KLA  ATP  ATP+KLA
 AF107847 neuroendocrine-specific Golgi protein p55 isoform 1 (XLalphas) alternatively spliced mRNA, complete cds. [AF107847] KLA 1.04 .94 1.00 1.05 1.04 .98 1.00
ATP .98 .97 .96 1.00 .99 .98 1.02
KLA/ATP 1.04 1.02 .96 .95 1.01 .96 1.01
Gnas
KLA  ATP  ATP+KLA
 AK017423 10 days neonate head cDNA, RIKEN full-length enriched library, clone:5530400H20 product:novel noncoding RNA overlapping the exon 1A, 1 and 2 of Gnas, full insert sequence. [AK017423] KLA .85 1.08 .97 .92 1.05 1.03 1.08
ATP .99 1.30 2.11 1.73 1.23 1.01 1.02
KLA/ATP .96 1.06 1.58 1.34 1.29 1.05 .91
Gnas
KLA  ATP  ATP+KLA
 NM_001077510 GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus (Gnas), transcript variant 8, mRNA [NM_001077510] KLA .99 1.03 .97 .91 1.03 .95 .97
ATP 1.04 1.19 1.15 1.61 1.24 .91 1.00
KLA/ATP 1.06 .97 1.01 1.46 1.04 .85 1.01
Gnas
KLA  ATP  ATP+KLA
 S49980 gb|stimulatory G protein alpha subunit {clone WC-16} [mice, whole cochlea, mRNA Partial, 356 nt]. [S49980] KLA .91 .88 1.03 .87 .90 .84 1.01
ATP 1.16 1.22 1.02 1.55 1.16 .80 .99
KLA/ATP 1.01 1.13 .86 1.12 .97 .85 1.08
Gper
KLA  ATP  ATP+KLA
 NM_029771 G protein-coupled estrogen receptor 1 (Gper), mRNA [NM_029771] KLA .89 .95 .95 .96 1.01 1.16 1.16
ATP .98 .92 1.08 .95 1.03 1.16 1.08
KLA/ATP .88 .95 1.04 .91 1.05 1.07 1.02
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Grm1
KLA  ATP  ATP+KLA
 NM_016976 glutamate receptor, metabotropic 1 (Grm1), transcript variant 1, mRNA [NM_016976] KLA 1.16 1.07 1.10 1.18 1.08 1.04 1.15
ATP 1.06 1.05 1.02 .99 1.00 1.09 1.02
KLA/ATP 1.04 1.12 1.06 1.11 1.10 1.32 1.35
Hbegf
KLA  ATP  ATP+KLA
 NM_010415 heparin-binding EGF-like growth factor (Hbegf), mRNA [NM_010415] KLA 4.85 5.22 4.43 2.64 1.67 1.05 .85
ATP 1.16 1.29 9.30 21.54 19.63 14.93 4.45
KLA/ATP 5.32 5.51 13.94 26.41 22.89 13.95 5.50
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Hsp90aa1
KLA  ATP  ATP+KLA
 NM_010480 heat shock protein 90, alpha (cytosolic), class A member 1 (Hsp90aa1), mRNA [NM_010480] KLA .95 1.03 .90 .92 .80 .94 .99
ATP .96 .92 1.39 1.21 2.02 3.66 1.10
KLA/ATP .93 .92 1.32 1.01 1.85 2.21 1.20
Hsp90ab1
KLA  ATP  ATP+KLA
 NM_008302 heat shock protein 90kDa alpha (cytosolic), class B member 1 (Hsp90ab1), mRNA [NM_008302] KLA .93 1.02 .98 .82 .95 1.10 1.39
ATP 1.04 1.14 .92 1.32 1.19 1.02 .63
KLA/ATP 1.02 1.04 .80 1.12 .87 .86 .75
Hsp90b1
KLA  ATP  ATP+KLA
 NM_011631 heat shock protein 90, beta (Grp94), member 1 (Hsp90b1), mRNA [NM_011631] KLA .78 .83 .71 .69 .73 .69 .80
ATP 1.00 1.08 1.01 .94 .84 .84 .66
KLA/ATP .78 .82 .81 .73 .66 .68 .27
Hspa1a
KLA  ATP  ATP+KLA
 NM_010479 heat shock protein 1A (Hspa1a), mRNA [NM_010479] KLA 7.88 6.99 4.47 5.18 7.81 11.47 4.14
ATP 1.88 5.62 43.42 58.76 55.53 28.89 9.13
KLA/ATP 7.40 7.62 28.23 54.12 70.14 43.09 22.49
Hspa1b
KLA  ATP  ATP+KLA
 NM_010478 heat shock protein 1B (Hspa1b), mRNA [NM_010478] KLA 5.01 4.73 3.77 3.62 4.81 6.53 3.12
ATP 1.34 3.07 14.11 17.14 17.51 11.21 4.82
KLA/ATP 5.04 5.15 11.63 19.94 20.84 15.79 9.30
Hspa1l
KLA  ATP  ATP+KLA
 NM_013558 heat shock protein 1-like (Hspa1l), mRNA [NM_013558] KLA .98 1.04 1.10 1.21 1.51 1.97 1.86
ATP 1.03 1.08 1.07 1.14 .93 1.21 1.89
KLA/ATP 1.06 1.01 .99 1.09 .97 1.39 2.87
Hspa2
KLA  ATP  ATP+KLA
 NM_008301 heat shock protein 2 (Hspa2), transcript variant 1, mRNA [NM_008301] KLA .98 .97 1.12 1.23 1.20 1.72 1.38
ATP 1.01 1.10 1.45 3.12 2.45 1.98 .98
KLA/ATP .99 1.12 1.52 2.60 2.89 2.62 1.18
Hspa8
KLA  ATP  ATP+KLA
 NM_031165 heat shock protein 8 (Hspa8), mRNA [NM_031165] KLA 1.00 .98 1.27 1.18 1.45 1.60 1.31
ATP 1.22 1.18 1.07 1.44 1.07 .53 .57
KLA/ATP 1.18 1.22 1.14 1.08 .93 .82 .77
Itpr1
KLA  ATP  ATP+KLA
 NM_010585 inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585] KLA 3.66 3.69 6.74 8.11 7.08 4.40 1.22
ATP 1.08 .95 1.19 .94 1.09 1.00 .68
KLA/ATP 3.48 3.58 5.86 6.03 4.01 2.31 .97
Itpr2
KLA  ATP  ATP+KLA
 NM_019923 inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923] KLA 1.41 1.38 1.43 1.42 1.30 1.07 1.01
ATP 1.00 1.00 .97 .97 1.07 1.15 1.06
KLA/ATP 1.39 1.48 1.64 1.42 1.07 .83 .95
Itpr3
KLA  ATP  ATP+KLA
 NM_080553 inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553] KLA .55 .51 .45 .41 .34 .34 .45
ATP 1.01 .92 1.02 .57 .46 .34 1.22
KLA/ATP .56 .48 .48 .29 .33 .27 .65
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Kcnj3
KLA  ATP  ATP+KLA
 BC068167 potassium inwardly-rectifying channel, subfamily J, member 3, mRNA (cDNA clone MGC:92970 IMAGE:30543982), complete cds [BC068167] KLA .99 .97 1.01 .94 .97 .99 .99
ATP 1.06 1.01 1.03 .82 1.01 1.00 .94
KLA/ATP .98 .91 .99 .99 1.01 1.11 .97
Kcnj3
KLA  ATP  ATP+KLA
 NM_008426 potassium inwardly-rectifying channel, subfamily J, member 3 (Kcnj3), mRNA [NM_008426] KLA 1.05 .99 1.04 1.02 1.02 1.04 .94
ATP 1.00 1.01 1.02 .99 .96 1.03 1.04
KLA/ATP 1.00 .98 1.03 1.02 1.02 .96 1.06
Kcnj5
KLA  ATP  ATP+KLA
 NM_010605 potassium inwardly-rectifying channel, subfamily J, member 5 (Kcnj5), mRNA [NM_010605] KLA 1.06 1.07 .97 .97 .99 1.05 .98
ATP .96 1.11 1.09 .98 .95 1.03 1.05
KLA/ATP .98 1.00 1.10 .98 1.07 .96 1.02
Kcnj6
KLA  ATP  ATP+KLA
 NM_001025585 potassium inwardly-rectifying channel, subfamily J, member 6 (Kcnj6), transcript variant Girk2B, mRNA [NM_001025585] KLA .97 .96 .95 .96 .98 .96 .95
ATP 1.00 .98 1.02 1.00 .98 .96 .97
KLA/ATP .98 .95 .99 .96 .98 .93 .96
Kcnj6
KLA  ATP  ATP+KLA
 NM_010606 potassium inwardly-rectifying channel, subfamily J, member 6 (Kcnj6), transcript variant Girk2A-1, mRNA [NM_010606] KLA .96 1.03 .97 .98 .97 .99 1.07
ATP 1.08 .99 .99 1.05 .96 1.04 .97
KLA/ATP 1.01 .92 1.03 1.03 1.04 1.03 1.08
Kcnj9
KLA  ATP  ATP+KLA
 AK007011 adult male testis cDNA, RIKEN full-length enriched library, clone:1700085N21 product:unclassifiable, full insert sequence. [AK007011] KLA 1.00 1.03 .98 1.02 .95 1.09 1.01
ATP .97 .92 1.03 1.11 1.02 .95 1.01
KLA/ATP 1.01 .98 .98 1.05 1.07 1.03 1.02
Kcnj9
KLA  ATP  ATP+KLA
 NM_008429 potassium inwardly-rectifying channel, subfamily J, member 9 (Kcnj9), mRNA [NM_008429] KLA 1.03 1.06 1.06 1.07 1.09 .95 1.00
ATP 1.02 .93 .93 1.14 1.07 .98 .95
KLA/ATP 1.03 .99 .99 1.02 1.02 .96 .96
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.28968
1
KLA  ATP  ATP+KLA
 6754177 Unknown KLA 5.70 5.98 5.26 3.13 1.73 .87 .76
ATP 1.12 1.23 10.71 22.34 24.13 18.42 4.28
KLA/ATP 5.68 6.39 18.15 29.48 26.96 19.85 6.17
Mm.41137
KLA  ATP  ATP+KLA
 148747308 Unknown KLA 1.03 1.00 .95 .92 1.04 .98 .96
ATP 1.02 .98 .98 .90 .95 .92 1.07
KLA/ATP .91 .89 1.01 .95 1.00 .96 .99
Mm.41274
5
KLA  ATP  ATP+KLA
 110681696 Unknown KLA .97 1.07 1.11 1.07 1.38 1.63 1.35
ATP 1.06 1.09 1.05 1.29 1.04 .50 .56
KLA/ATP 1.11 1.12 1.04 1.11 .92 .83 .74
Mm.44160
1
KLA  ATP  ATP+KLA
 145966786 Unknown KLA 1.08 .94 1.01 .97 .79 .78 .71
ATP 1.09 .92 1.10 .75 .65 .92 .69
KLA/ATP 1.01 .92 1.16 .81 .69 .56 .63
Mmp2
KLA  ATP  ATP+KLA
 NM_008610 matrix metallopeptidase 2 (Mmp2), mRNA [NM_008610] KLA 1.12 1.24 1.48 1.26 1.44 1.19 1.09
ATP 1.05 1.01 1.07 1.08 .93 1.01 1.14
KLA/ATP 1.23 1.26 1.16 1.15 .95 1.11 1.04
Mmp9
KLA  ATP  ATP+KLA
 NM_013599 matrix metallopeptidase 9 (Mmp9), mRNA [NM_013599] KLA 1.49 1.65 1.43 1.32 1.46 1.33 2.10
ATP 1.03 1.05 1.12 1.36 1.17 2.27 5.92
KLA/ATP 1.51 1.64 1.35 1.78 1.34 1.20 2.96
Nos3
KLA  ATP  ATP+KLA
 NM_008713 nitric oxide synthase 3, endothelial cell (Nos3), mRNA [NM_008713] KLA .83 .79 .76 .78 .77 .85 .96
ATP 1.03 1.09 1.03 1.02 .85 .96 1.84
KLA/ATP .80 .78 .79 .80 .79 .78 .91
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Oprm1
KLA  ATP  ATP+KLA
 NM_001039652 opioid receptor, mu 1 (Oprm1), mRNA [NM_001039652] KLA .98 1.04 .94 .96 .93 .94 1.03
ATP .89 .92 1.06 .98 1.00 1.04 1.01
KLA/ATP .94 .97 1.05 1.00 1.02 1.01 1.00
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Plcb1
KLA  ATP  ATP+KLA
 AK129166 mRNA for mKIAA0581 protein [AK129166] KLA 1.02 .98 .91 .91 .92 .95 .89
ATP 1.03 1.02 1.02 1.01 .90 1.02 1.04
KLA/ATP .98 .97 .91 .93 .92 1.01 1.16
Plcb1
KLA  ATP  ATP+KLA
 NM_019677 phospholipase C, beta 1 (Plcb1), mRNA [NM_019677] KLA .99 .94 .95 .97 .93 .92 .91
ATP 1.00 .96 .99 .95 .99 1.03 .98
KLA/ATP .93 .96 .94 .93 .87 1.00 1.06
Plcb2
KLA  ATP  ATP+KLA
 NM_177568 phospholipase C, beta 2 (Plcb2), mRNA [NM_177568] KLA .70 .68 .64 .67 .65 .76 .88
ATP .95 .94 1.04 .94 .72 .57 1.19
KLA/ATP .69 .68 .72 .63 .65 .55 .70
Plcb3
KLA  ATP  ATP+KLA
 NM_008874 phospholipase C, beta 3 (Plcb3), mRNA [NM_008874] KLA 1.72 1.78 1.82 1.65 1.67 1.44 1.21
ATP .97 1.04 .81 .87 .78 .88 .94
KLA/ATP 1.69 1.89 1.44 1.66 1.12 .73 .93
Plcb4
KLA  ATP  ATP+KLA
 AK082509 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509] KLA 1.06 1.03 .97 .98 1.02 1.01 .99
ATP .99 1.07 1.09 .95 .97 .97 1.02
KLA/ATP .98 1.00 1.03 .96 1.02 .91 .98
Plcb4
KLA  ATP  ATP+KLA
 NM_013829 phospholipase C, beta 4 (Plcb4), mRNA [NM_013829] KLA .88 .94 .81 .82 .81 .86 1.01
ATP 1.00 1.01 .92 .93 .88 .85 .89
KLA/ATP .97 .94 .78 .80 .78 .86 .97
Prkaca
KLA  ATP  ATP+KLA
 NM_008854 protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] KLA .71 .74 .72 .70 .72 .84 .85
ATP 1.05 .98 .89 .92 .76 .60 1.02
KLA/ATP .79 .74 .55 .65 .60 .65 .93
Prkacb
KLA  ATP  ATP+KLA
 NM_011100 protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] KLA .69 .70 .66 .58 .51 .55 .59
ATP 1.02 1.19 .97 1.01 .69 .38 .56
KLA/ATP .72 .73 .57 .62 .47 .41 .45
Prkcd
KLA  ATP  ATP+KLA
 NM_011103 protein kinase C, delta (Prkcd), mRNA [NM_011103] KLA 1.72 1.84 1.90 1.68 2.01 1.61 1.64
ATP 1.00 1.03 .68 .81 1.38 1.26 .98
KLA/ATP 1.77 1.79 1.16 1.19 1.33 1.25 1.56
Prkx
KLA  ATP  ATP+KLA
 NM_016979 protein kinase, X-linked (Prkx), mRNA [NM_016979] KLA 3.61 3.79 4.67 4.66 4.85 4.19 1.43
ATP .98 .90 .63 .61 1.12 1.90 1.29
KLA/ATP 3.56 3.36 2.62 2.06 2.26 2.87 2.31
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Shc1
KLA  ATP  ATP+KLA
 NM_011368 src homology 2 domain-containing transforming protein C1 (Shc1), transcript variant 2, mRNA [NM_011368] KLA .88 .87 .86 .83 1.09 1.11 1.12
ATP 1.04 1.25 .85 1.17 .93 1.16 1.00
KLA/ATP .93 .96 .62 .96 .75 1.25 1.19
Shc2
KLA  ATP  ATP+KLA
 NM_001024539 src homology 2 domain-containing transforming protein C2 (Shc2), mRNA [NM_001024539] KLA 1.19 1.25 1.22 1.16 1.15 1.14 .98
ATP 1.04 1.14 1.15 1.53 1.29 1.06 1.09
KLA/ATP 1.26 1.24 1.26 1.49 1.31 1.30 1.30
Shc3
KLA  ATP  ATP+KLA
 NM_009167 src homology 2 domain-containing transforming protein C3 (Shc3), mRNA [NM_009167] KLA 1.00 .98 1.06 1.06 1.12 1.08 1.04
ATP .99 1.02 1.00 1.05 1.00 1.08 1.08
KLA/ATP 1.08 1.06 1.01 1.06 1.03 1.12 1.41
Shc4
KLA  ATP  ATP+KLA
 NM_199022 SHC (Src homology 2 domain containing) family, member 4 (Shc4), mRNA [NM_199022] KLA 1.03 1.03 1.01 1.06 1.09 1.03 1.06
ATP .99 1.00 1.03 1.02 1.04 1.04 1.01
KLA/ATP .98 .97 1.06 1.05 1.00 1.00 1.14
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Sp1
KLA  ATP  ATP+KLA
 NM_013672 trans-acting transcription factor 1 (Sp1), mRNA [NM_013672] KLA .81 .75 .67 .79 .89 1.00 .84
ATP .96 1.01 1.13 .93 1.30 1.51 .84
KLA/ATP .73 .74 .81 .66 1.38 1.34 1.20
Src
KLA  ATP  ATP+KLA
 NM_009271 Rous sarcoma oncogene (Src), transcript variant 1, mRNA [NM_009271] KLA 6.99 7.23 7.54 5.99 5.34 3.39 3.00
ATP 1.02 1.06 1.06 2.08 4.41 5.03 3.97
KLA/ATP 7.44 7.51 5.48 6.24 4.86 5.86 7.90